IL314741A - Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease - Google Patents

Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease

Info

Publication number
IL314741A
IL314741A IL314741A IL31474124A IL314741A IL 314741 A IL314741 A IL 314741A IL 314741 A IL314741 A IL 314741A IL 31474124 A IL31474124 A IL 31474124A IL 314741 A IL314741 A IL 314741A
Authority
IL
Israel
Prior art keywords
synuclein
mhc
parkinson
induction
disease
Prior art date
Application number
IL314741A
Other languages
English (en)
Hebrew (he)
Original Assignee
Julius Maximilians Universit?T W?Rzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Julius Maximilians Universit?T W?Rzburg filed Critical Julius Maximilians Universit?T W?Rzburg
Publication of IL314741A publication Critical patent/IL314741A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL314741A 2022-03-24 2023-03-24 Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease IL314741A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22164123.6A EP4249506A1 (en) 2022-03-24 2022-03-24 Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease
PCT/EP2023/057682 WO2023180548A1 (en) 2022-03-24 2023-03-24 Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease

Publications (1)

Publication Number Publication Date
IL314741A true IL314741A (en) 2024-10-01

Family

ID=81384775

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314741A IL314741A (en) 2022-03-24 2023-03-24 Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease

Country Status (12)

Country Link
US (1) US20250205321A1 (enExample)
EP (2) EP4249506A1 (enExample)
JP (1) JP2025514872A (enExample)
KR (1) KR20240162549A (enExample)
CN (1) CN119317639A (enExample)
AU (1) AU2023238805A1 (enExample)
CA (1) CA3250917A1 (enExample)
CL (1) CL2024002724A1 (enExample)
CO (1) CO2024012329A2 (enExample)
IL (1) IL314741A (enExample)
MX (1) MX2024011665A (enExample)
WO (1) WO2023180548A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025061918A1 (en) * 2023-09-22 2025-03-27 Julius-Maximilians-Universität Würzburg Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3063959A1 (en) 2017-05-23 2018-11-29 Julius-Maximilians-Universitat Wurzburg Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation

Also Published As

Publication number Publication date
EP4499682A1 (en) 2025-02-05
AU2023238805A1 (en) 2024-07-18
WO2023180548A1 (en) 2023-09-28
CL2024002724A1 (es) 2025-02-14
KR20240162549A (ko) 2024-11-15
JP2025514872A (ja) 2025-05-12
US20250205321A1 (en) 2025-06-26
CA3250917A1 (en) 2023-09-28
CN119317639A (zh) 2025-01-14
EP4249506A1 (en) 2023-09-27
CO2024012329A2 (es) 2024-09-30
MX2024011665A (es) 2024-09-27

Similar Documents

Publication Publication Date Title
EP3820537A4 (en) GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE
MX375424B (es) Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl
EP3924371A4 (en) GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE
EP3854418A4 (en) TREATMENT OF HER3 MUTANT CANCER BY ADMINISTRATION OF ANTI-HER3 ANTIBODY-DRUG CONJUGATE
MA55375A (fr) Méthodes thérapeutiques de traitement de l'hépatite b
EP3760233A4 (en) ONE-POT PROCESS FOR THE PRODUCTION OF AN INTERMEDIATE ANTIBODY-ACTIVE CONJUGATE
IL309208A (en) Neuroactive steroid for the treatment of alzheimer's disease
EP4247357A4 (en) Method for treatment of parkinson's disease
IL309468A (en) Biomarkers for alzheimer's disease treatment
MA52137A (fr) Méthodes de traitement de l'amylose ttr à l'aide d'ag10
EP3980069A4 (en) METHODS OF TREATMENT OF SPLENOMEGALY
EP3833435A4 (en) DETERMINATION OF PARKINSON'S DISEASE
EP3648769A4 (en) HUMAN INTESTINAL FLORA-DERIVED N-ACYLAMIDES FOR THE TREATMENT OF HUMAN DISEASES
EP4211162A4 (en) TREATMENT OF PARKINSON'S DISEASE
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
EP4370131A4 (en) METHODS FOR TREATING ALZHEIMER'S DISEASE
MA54827A (fr) Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl
EP3809838A4 (en) GENETICALLY MODIFIED MOUSE MODELS OF ALZHEIMER'S DISEASE
EP4021920A4 (en) IMPROVED PROCESS FOR PRODUCTION OF ETELCALCETIDE HYDROCHLORIDE
PL4284387T3 (pl) Terapia podnosząca poziom NAD w chorobie Parkinsona
EP3852722A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF PARKINSON'S DISEASE
MX2018015397A (es) Co-cristales de benzoato de sodio y sus usos.
EP4304457A4 (en) TREATMENT OF PARKINSON'S DISEASE
EP3917502A4 (en) METHOD OF TREATMENT OF A PATIENT WITH PARKINSON'S DISEASE
MX2023000698A (es) Uso terapeutico del derivado de glucagon o conjugado del mismo para enfermedades hepaticas.